Download PDF
Semin Thromb Hemost 2014; 40(03): 332-336
DOI: 10.1055/s-0034-1370792
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Unique Hemostatic Dysfunction in Acute Promyelocytic Leukemia

Hau C. Kwaan
1   Division of Hematology/Oncology, Olson Pavilion, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
03 March 2014 (online)

    Permissions and Reprints

Abstract

The hemostatic abnormalities seen in acute promyelocytic leukemia (APL) are unique and account for much of the morbidity and mortality of this disorder. Almost all patients present at diagnosis with laboratory findings of intravascular coagulation along with increased fibrinolysis. This unusual combination is correlated to the clinical manifestations with high risk of both bleeding and thrombosis. Recent studies have revealed that the leukemic promyelocytes in APL express increased amounts of tissue factor as well as elements of the fibrinolytic system, including tissue plasminogen activator, annexin A2, and plasminogen activator inhibitor type 1. These changes are responsive to differentiation therapy with all-trans-retinoic acid (ATRA) or with arsenic trioxide (ATO). Despite a dramatic reduction in mortality seen since the introduction of differentiation therapy with ATRA or with ATO, a large number of deaths still occur before complete remission is achieved. The early deaths are mostly attributable to the presenting coagulopathy. The prevention and management of this hemostatic abnormality have thus far been unsuccessful and remain a challenge to bring about a higher cure rate for this disease.

Keywords

acute promyelocytic leukemia - tissue factor - fibrinolysis - tPA - annexin A2
 

  • References

  • 1 Croizat P, Favre-Gilly J, Morel P. Les aspects du syndrome hemorrhagiue des leucemies. Sang 1949; 20: 417-421
    PubMedGoogle Scholar
  • 2 Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159 (3) 189-194
    CrossrefPubMedGoogle Scholar
  • 3 Rand JJ, Moloney WD, Sise HS. Coagulation defects in acute promyelocytic leukemia. Arch Intern Med 1969; 123 (1) 39-47
    CrossrefPubMedGoogle Scholar
  • 4 Di Bona E, Avvisati G, Castaman G , et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108 (4) 689-695
    CrossrefPubMedGoogle Scholar
  • 5 Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22 (1) 153-163
    CrossrefPubMedGoogle Scholar
  • 6 Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156 (1) 24-36
    CrossrefPubMedGoogle Scholar
  • 7 Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012; 87 (6) 596-603
    CrossrefPubMedGoogle Scholar
  • 8 Kwaan HC, Huyck T. Thromboembolic and bleeding complications in acute leukemia. Expert Rev Hematol 2010; 3 (6) 719-730
    CrossrefPubMedGoogle Scholar
  • 9 Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia – what have we learned in the past twenty years. Bailliere's Best Practice & Research in Clinical Hematology on Acute Promyelocytic Leukemia 2014; ; In press
    PubMedGoogle Scholar
  • 10 de la Serna J, Montesinos P, Vellenga E , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111 (7) 3395-3402
    CrossrefPubMedGoogle Scholar
  • 11 Fenaux P. Management of acute promyelocytic leukemia. Eur J Haematol 1993; 50 (2) 65-73
    PubMedGoogle Scholar
  • 12 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91 (9) 3093-3102
    PubMedGoogle Scholar
  • 13 Yanada M, Matsushita T, Asou N , et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78 (3) 213-219
    CrossrefPubMedGoogle Scholar
  • 14 De Stefano V, Sorà F, Rossi E , et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3 (9) 1985-1992
    CrossrefPubMedGoogle Scholar
  • 15 Ziegler S, Sperr WR, Knöbl P , et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115 (1-2) 59-64
    CrossrefPubMedGoogle Scholar
  • 16 Breccia M, Avvisati G, Latagliata R , et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21 (1) 79-83
    CrossrefPubMedGoogle Scholar
  • 17 Riccio JA, Colley AT, Cera PJ. Hepatic vein thrombosis (Budd-Chiari syndrome) in the microgranular variant of acute promyelocytic leukemia. Am J Clin Pathol 1989; 92 (3) 366-371
    PubMedGoogle Scholar
  • 18 Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981; 57 (3) 518-525
    CrossrefPubMedGoogle Scholar
  • 19 Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64 (4) 791-796
    CrossrefPubMedGoogle Scholar
  • 20 Tallman MS, Lefèbvre P, Baine RM , et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2 (8) 1341-1350
    CrossrefPubMedGoogle Scholar
  • 21 Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001; 106 (1-2) 43-51
    CrossrefPubMedGoogle Scholar
  • 22 Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002; 20 (1) 33-41
    CrossrefPubMedGoogle Scholar
  • 23 Zhu J, Guo WM, Yao YY , et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999; 13 (7) 1062-1070
    CrossrefPubMedGoogle Scholar
  • 24 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25 (14) 4007-4020
    CrossrefPubMedGoogle Scholar
  • 25 Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115 (2) 382-391
    CrossrefPubMedGoogle Scholar
  • 26 Zhao W, Wang X, Guo W , et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl) 2000; 113 (3) 236-240
    PubMedGoogle Scholar
  • 27 Watanabe R, Murata M, Takayama N , et al; Keio Hematology-Oncology Cooperative Study Group (KHOCS). Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Thromb Haemost 1997; 77 (4) 641-645
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71 (4) 511-517
    CrossrefPubMedGoogle Scholar
  • 29 Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77 (9) 1949-1957
    PubMedGoogle Scholar
  • 30 Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70 (1) 43-48
    CrossrefPubMedGoogle Scholar
  • 31 Falanga A, Iacoviello L, Evangelista V , et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86 (3) 1072-1081
    PubMedGoogle Scholar
  • 32 Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011; 3 (1) e2011068
    CrossrefPubMedGoogle Scholar
  • 33 Booth NA, Bennett B. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol 1984; 56 (4) 545-556
    CrossrefPubMedGoogle Scholar
  • 34 Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340 (13) 994-1004
    CrossrefPubMedGoogle Scholar
  • 35 Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269 (33) 21191-21197
    PubMedGoogle Scholar
  • 36 Meijers JC, Oudijk EJ, Mosnier LO , et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108 (3) 518-523
    CrossrefPubMedGoogle Scholar
  • 37 Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost 2004; 2 (2) 306-312
    CrossrefPubMedGoogle Scholar
  • 38 Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36 (8) 917-924
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Ma G, Liu F, Lv L, Gao Y, Su Y. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 2013; 92 (5) 645-652
    CrossrefPubMedGoogle Scholar
  • 40 Dombret H, Scrobohaci ML, Ghorra P , et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7 (1) 2-9
    PubMedGoogle Scholar
  • 41 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75 (11) 2112-2117
    PubMedGoogle Scholar
  • 42 Sanz MA, Martín G, González M , et al; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103 (4) 1237-1243
    CrossrefPubMedGoogle Scholar
  • 43 Hashimoto S, Koike T, Tatewaki W , et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8 (7) 1113-1115
    PubMedGoogle Scholar
  • 44 Mahendra P, Keeling DM, Hood IM, Baglin TP, Marcus RE. Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Clin Lab Haematol 1996; 18 (1) 51-52
    CrossrefPubMedGoogle Scholar
  • 45 Brown JE, Olujohungbe A, Chang J , et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 2000; 110 (4) 1010-1012
    CrossrefPubMedGoogle Scholar
  • 46 Nosari A, Caimi TM, Zilioli V, Molteni A, Mancini V, Morra E. Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia. Leuk Lymphoma 2012; 53 (1) 160-161
    CrossrefPubMedGoogle Scholar
  • 47 Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004; 72 (6) 455-456
    CrossrefPubMedGoogle Scholar
  • 48 Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in PML. Am J Hematol 2006; 81 (9) 720
    PubMedGoogle Scholar
  • 49 Kawano N, Kuriyama T, Yoshida S , et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Intern Med 2013; 52 (1) 55-62
    CrossrefPubMedGoogle Scholar
  • 50 Saito H, Maruyama I, Shimazaki S , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (1) 31-41
    CrossrefPubMedGoogle Scholar
  • 51 Kawano N, Yoshida S, Ono N , et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. J Clin Exp Hematop 2011; 51 (2) 101-107
    CrossrefPubMedGoogle Scholar
  • 52 Sanz MA, Grimwade D, Tallman MS , et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (9) 1875-1891
    CrossrefPubMedGoogle Scholar
  • 53 Altman JK, Rademaker A, Cull E , et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37 (9) 1004-1009
    CrossrefPubMedGoogle Scholar
  • 54 Dunoyer-Geindre S, Kruithof EK. Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells. Cardiovasc Res 2011; 90 (3) 457-463
    CrossrefPubMedGoogle Scholar